Anti-thrombin Market to Grow With a CAGR of XX% Over the Forecast Period of 2019-
2025, Due to Increasing Incidence of Coagulation Disorders
Analyst Speak:
“ The Anti-thrombin Market is anticipated to reach about US$ XX Mn by 2025, and anticipated to expand
at a CAGR over seven years of forecast period 2019-2025” owing to an increasing incidence of coagulation
disorders.
Precision Business Insights (PBI) in its report titled “Anti-thrombin Market: Market Estimation,
Dynamics, Regional Share, Trends, Competitor Analysis 2013-2018 and Forecast 2019-2025” assesses the
market performance over seven years forecast period from 2019 to 2025. The report analyses the market
value forecast and provides the strategic insights into the market driving factors, challenges that are
hindering the anti-thrombin market revenue growth over forecast period.
The anti-thrombin market size was accounted for US$ XX Mn in 2018 and anticipated to account for US$
XX Mn by 2025. Increasing incidence of coagulation disorders, open heart surgeries, and extracorporeal
circulation during hemodialysis is augmenting growth of anti-thrombin market. According to the Centers
for Disease Control and Prevention (CDC), 2015, around 900,000 people is affected from venous
thromboembolism every year in the U.S. Therapeutic drug pipeline or advancements in drug administering
technology is also expected to fuel growth of anti-thrombin market. Furthermore, increasing use of anti-
thrombin in combination with heparin is likely to support the growth of anti-thrombin market. For instance,
heparin resistance in cardiac surgery is likely to create opportunities for use of anti-thrombin products in
anticoagulation therapy. However, increasing regulations on animal testing have impeded a number of
healthcare companies from manufacturing new drugs, thereby restraining the market growth.
Anti-thrombin market segmented on the basis of source, application, dosage form end user and regions.
Human Milk Source Segment Expected to Dominate the Market
Based on source, anti-thrombin market is as human, and goat milk. The human source, the segment is
estimated to account major shares in global antithrombin market in 2017. Humans are the major source of
anti-thrombin, but now a day’s goat milk became alternative for human source. Goats produce about 800
liters of milk per year. The yield of the active protein by goat model is 10X higher than cell culture model.
The transgenic goats are the excellent source for antithrombin production, as they produce plenty of milk
in short generation time, and these factors are responsible for the high growth of goat milk segment over
the forecast period. Currently, the goat milk produced antithrombins are available in developed countries
such as U.S., UK, and Germany. The increasing adoption of newer technologies and advanced products in
developing countries is expected to drive the growth of segment over the forecast period.
Read more Insights at https://precisionbusinessinsights.com/market-reports/antithrombin-market/
North America, Accounts for Major Revenue Share for Anti-thrombin Market
Precision Business Insights (PBI) anti-thrombin market report analyses the market in different regions
North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional
analysis, North America is expected to gain significant traction in the global anti-thrombin market, followed
by Europe, owing to adoption of robust developed technologies and antithrombin therapies, and high
awareness and increasing regulatory approval of drugs in these regions.